RxSight Dividends and Buybacks
Dividend criteria checks 0/6
RxSight does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-8.6%
Buyback Yield
| Total Shareholder Yield | -8.6% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Dec 06
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RXST's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RXST's dividend payments have been increasing.
Dividend Yield vs Market
| RxSight Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RXST) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Medical Equipment) | 1.8% |
| Analyst forecast (RXST) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate RXST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RXST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RXST's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RXST has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 11:02 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RxSight, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Michael Gorman | BTIG |
| Xuyang Li | Jefferies LLC |